Karachi: In a recent corporate briefing session, Liven Pharma Limited unveiled a series of strategic initiatives aimed at bolstering its market presence and operational capacity. The report, dated November 12, 2026, outlined a comprehensive plan focused on capital market and growth initiatives, highlighting the company's commitment to expanding its reach within the pharmaceutical industry.
The company's rights issue, valued at PKR 200 million, is expected to have a paid-up impact of approximately 21.5% of the current paid-up capital. This financial maneuver involves the issuance of 20 million shares at PKR 10 each. The funds generated from this rights issue are earmarked for several strategic purposes, including strengthening working capital to support scaling efforts, procuring vehicles and distribution assets, and launching extensive marketing campaigns. Additionally, Liven Pharma plans to enhance its engagement with healthcare professionals as part of its broader growth strategy.
According to information available from the Pakistan Stock Exchange (PSX), Liven Pharma Limited is set to introduce over 30 new products, focusing primarily on injectables through toll manufacturing, as well as specialized formulations. These initiatives reflect the company's focus on expanding its product pipeline and enhancing its market competitiveness.
The company also plans to undertake capital expenditures aimed at establishing a Dry Powder Injectables division. Regulatory licensing with the Drug Regulatory Authority of Pakistan (DRAP) is another key component of Liven Pharma's strategy, ensuring compliance and facilitating the introduction of new products. Moreover, the expansion of its distribution network across Pakistan is set to further solidify the company's market position.
Liven Pharma Limited's shareholding structure reveals a significant majority held by sponsors, accounting for 86.8% of the shares. Individuals hold 3.53%, while the free float represents 5.0%, and physical shares account for 4.67%. This structure underscores the company's stability and the strong backing from its sponsors.
The designated market category for Liven Pharma Limited remains focused on the pharmaceutical sector, with specific attention to the development and distribution of injectables and specialized formulations. As the company moves forward with its ambitious plans, it aims to reinforce its position as a key player in the industry, leveraging new capital strategies to drive growth and innovation.